Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.

Article Details

Citation
Copy to clipboard

Pelaia C, Pelaia G, Crimi C, Maglio A, Gallelli L, Terracciano R, Vatrella A

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.

Int J Mol Sci. 2021 Apr 22;22(9). pii: ijms22094369. doi: 10.3390/ijms22094369.

PubMed ID
33922072 [ View in PubMed
]
Abstract

Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation. Released from airway epithelial cells upon tissue damage induced by several noxious agents including allergens, viruses, bacteria, and airborne pollutants, TSLP activates dendritic cells and group 2 innate lymphoid cells involved in the pathobiology of T2-high asthma. Tezepelumab is a fully human monoclonal antibody that binds to TSLP, thereby preventing its interaction with the TSLP receptor complex. Preliminary results of randomized clinical trials suggest that tezepelumab is characterized by a good safety and efficacy profile in patients with severe, uncontrolled asthma.

DrugBank Data that Cites this Article

Drugs